Device Trial Radar · NCT05848284
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Apr 1, 2024
Primary completion
Nov 30, 2026
Study completion Nov 30, 2031
Sponsor
- Lead sponsor
- VDyne, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 8, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
Conditions
- Tricuspid Regurgitation
- Tricuspid Valve Disease
- Tricuspid Valvular Disorders
Interventions
VDyne Transcatheter Tricuspid Valve Replacement SystemDevice
The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB. The valve is repositionable and fully retrievable intraoperatively. Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).Time frame: Implant to 30 days post-procedure
- Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core LabsTime frame: Baseline to 1 month after implant
- Changes in symptom status (NYHA class)Time frame: Baseline to 1 month after implant
2 more outcomes with a free account
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Henry Ford Hospital
Detriot, Michigan · Active not recruiting
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota · Active not recruiting
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.